Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIL06v
- Development stage
- Unknown
- Lead developer
- Biosceptre International
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptides, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous Injection
01
Overview
BIL06v is a therapeutic peptide-protein conjugate vaccine developed for the treatment of cancer, specifically advanced solid tumors. It is designed to stimulate the immune system to generate antibodies against non-functional P2X7 receptors (nfP2X7), which are expressed on cancer cells but not on most normal tissues. By targeting nfP2X7, BIL06v aims to induce an anti-tumor immune response and inhibit tumor growth. The vaccine is administered subcutaneously and has been evaluated in phase 1 clinical trials for safety, tolerability, immunogenicity, and anti-tumor activity in patients with advanced solid tumors[1][2][3][5][6].
02
Targets
nfP2X7 (Purinergic P2X7 receptor (non-functional form))
Beyond the preview
Go deeper on BIL06v.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIL06v.